Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
Invited speaker from Salipro at Discovery & Development Europe 2026
2026-05-26
Salipro Biotech is heading to Discovery & Development Europe 2026 (June 15-16), happening in Berlin, Germany!
Will you be there?
Join our CEO Jens Frauenfeld on stage, on Tuesday June 16 at 14:50, who will present how the Salipro® platform enables advanced DEL-based discovery and validation of native ion channel modulators.
In addition, our Scientist Mia Abramsson will be presenting a poster during the conference.
Interested in drug discovery towards complex membrane protein targets or the Salipro® platform? Let’s connect in Berlin!
Salipro Biotech announces yet another research collaboration
2026-05-19
Salipro Biotech has entered into yet another research collaboration agreement with a Gene Therapy Biotech company in the USA. Within this new collaboration, the Salipro® platform will be used to evaluate therapeutic antibodies to improve cell-based gene therapies.
We look forward to the advancements this project will contribute to our core mission: making the undruggable druggable.
Salipro Biotech announces a new research collaboration
2026-05-08
Salipro Biotech has entered into a new research collaboration agreement with a Next-Generation Biotech company in the USA. Within this new collaboration, the Salipro® platform will be used in combination with the company's Machine Learning platform to develop drug candidates against a GPCR target.
We look forward to the advancements that this collaboration will bring in our commitment to make the undruggable druggable!